Erythromycin 250 primarily targets bacteria by inhibiting protein synthesis. It does this by binding to the 50S subunit of bacterial ribosomes, specifically to the 23S rRNA component. This binding interferes with the movement of ribosomes along the mRNA strand during protein synthesis, disrupting the production of essential proteins necessary for bacterial growth and survival.

By targeting the ribosomes, Erythromycin prevents bacteria from synthesizing new proteins needed for their reproduction and functioning. This leads to a halt in bacterial growth and allows the body's immune system to effectively eliminate the bacteria.

It's important to note that Erythromycin specifically targets bacterial ribosomes and has minimal effect on human ribosomes. This selective targeting ensures that Erythromycin primarily affects bacterial cells while minimizing potential harm to human cells.

In summary, Erythromycin 250 targets bacterial ribosomes, inhibits protein synthesis, and ultimately disrupts the growth and survival of bacteria.